Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Magenta Therapeutics, Inc. MGTA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
26/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Magenta Therapeutics, Inc. (MGTA) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 4 Buy, 6 Hold.

MGTA Analyst Ratings

Hold
10
Ratings
4 Buy
6 Hold
Based on 10 analysts giving stock ratings to Magenta Therapeutics, Inc. in the past 3 months
Rating breakdown
Buy
4 40%
Hold
6 60%
40%
Buy
4 analysts
60%
Hold
6 analysts
0%
Sell
0 analysts

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 SPRO
SPRO
Spero Therapeutics, Inc.
$2.78
-0.36%
 ACHL
ACHL
Achilles Therapeutics plc
$1.48
+0.68%
 TIL
TIL
Instil Bio, Inc.
$8.44
+1.02%
 NXTC
NXTC
NextCure, Inc.
$12.77
+3.65%
 NLTX
NLTX
Neoleukin Therapeutics, Inc.
$3.49
+1.45%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message